Cipla (CIPLA) Q4 18/19 earnings summary

Executive summary

• FY18-19 revenue reached ₹16,362 crore, up 8% YoY; EBITDA was ₹3,171 crore at 19.4% of sales, and PAT attributable to shareholders rose 8% to ₹1,528 crore.

• India, South Africa’s private market and North America anchored growth; emerging-market performance was pressured by Middle East challenges, while tender businesses faced pricing pressure.

• Strategic priorities included differentiated US generics and specialty products, growth in chronic therapies, and expansion in China and Brazil.

Financial highlights

• Consolidated revenue from operations was ₹16,362 crore versus ₹15,219 crore in FY17-18, up 8%; EBITDA rose 12% to ₹3,171 crore.

• Reported EBITDA margin expanded ~80 bps YoY to 19.4%; normalized base-business EBITDA grew in double digits, excluding limited-launch benefits and one-time charges.

• PAT attributable to shareholders increased 8% to ₹1,528 crore; diluted EPS rose 8% to ₹18.93.

• Cash flow from operations increased 16% to ₹1,691 crore, supported by inventory management and higher profitability.

• Consolidated profit for the year was ₹1,492 crore after a ₹17 crore share of associate losses; PAT attributable to owners was ₹1,528 crore.

Outlook and guidance

• FY19-20 outlook calls for continued growth across focused markets, including above-market growth in selected India therapies and continued strength in South Africa’s private market.

• US generics guidance targets double-digit growth, supported by FY18-19 launches and FY19-20 launches; specialty investment will continue.

• EBITDA margin expansion is expected over normalized FY18-19 EBITDA; planned R&D spend is 7%-8% of revenue, with 12+ ANDA filings.

• Respiratory and specialty investment will continue in the US; China and Brazil entries are planned, with risks in Middle Eastern markets to be managed.